mounjaro o tirzepatide (tirzepatide) for the Treatment of Type 2 Diabetes, USA Tirzepatide (Mounjaro) In Sherman Oaks

Colleen McCabe, PharmD, BCOP, and Lindsay Mundy, PharmD, BCOP, provided an engaging exploration of the benefits and potential pitfalls seen with the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in an oncology setting

This review provides an overview of weight loss interventions and discusses their use in the context of gestation, such as surgical interventions and anti-obesity medications

Roches oral GLP-1 receptor agonist CT-996obtained in the $2.7 billion acquisition of Carmot Therapeuticsreduced body weight by more than 6% at four weeks versus placebo in a Phase I trial.

Semaglutide Informed Consent Continued Pg 4

Each Mounjaro vial contains: 5 mg of tirzepatide as active ingredient and excipients necessary for the formulation

Methods This was a single-center, retrospective cohort study involving adults with type 2 diabetes who received an escalated once-weekly semaglutide dose from 0.5 to 1.0 mg in routine clinical care